William Meury Net Worth

The estimated Net Worth of William Meury is at least $14.7 Milion dollars as of 2 August 2023. Mr. Meury owns over 83,000 units of Syndax Pharmaceuticals Inc stock worth over $1,319,040 and over the last 9 years he sold SNDX stock worth over $13,233,006. In addition, he makes $174,246 as Independent Director at Syndax Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Meury SNDX stock SEC Form 4 insiders trading

William has made over 5 trades of the Syndax Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 83,000 units of SNDX stock worth $665,660 on 2 August 2023.

The largest trade he's ever made was exercising 83,000 units of Syndax Pharmaceuticals Inc stock on 2 August 2023 worth over $665,660. On average, William trades about 6,549 units every 84 days since 2015. As of 2 August 2023 he still owns at least 72,000 units of Syndax Pharmaceuticals Inc stock.

You can see the complete history of Mr. Meury stock trades at the bottom of the page.

William Meury biography

William J. Meury serves as Independent Director of the Company. Mr. Meury has served as the Chief Commercial Officer of Allergan, plc, a global pharmaceutical company. Mr. Meury previously served as President, Branded Pharma from March 2015 to May 2016 and joined Allergan in July 2014 as Executive Vice President, Commercial, North American Brands. He has significant experience in launching and commercializing healthcare products. Prior to joining Allergan, Mr. Meury served as Executive Vice President, Sales and Marketing at Forest Laboratories, Inc. He joined Forest in 1993 and held multiple roles of increasing responsibility in Marketing, New Products, Business Development, and Sales. Before joining Forest, Mr. Meury worked in public accounting for Reznick Fedder & Silverman and in financial reporting for MCI Communications. Mr. Meury is currently on the board of directors of several organizations, including The Jed Foundation and the International Council of Ophthalmology Foundation. Mr. Meury earned his B.S. in economics from the University of Maryland.

What is the salary of William Meury?

As the Independent Director of Syndax Pharmaceuticals Inc, the total compensation of William Meury at Syndax Pharmaceuticals Inc is $174,246. There are 8 executives at Syndax Pharmaceuticals Inc getting paid more, with Michael Metzger having the highest compensation of $2,696,890.

How old is William Meury?

William Meury is 52, he's been the Independent Director of Syndax Pharmaceuticals Inc since 2018. There are 8 older and 8 younger executives at Syndax Pharmaceuticals Inc. The oldest executive at Syndax Pharmaceuticals Inc is Dr. Michael L. Meyers M.D., Ph.D., 70, who is the Chief Medical Officer & Sr. VP.

What's William Meury's mailing address?

William's mailing address filed with the SEC is C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON, MA, 02110.

Insiders trading at Syndax Pharmaceuticals Inc

Over the last 9 years, insiders at Syndax Pharmaceuticals Inc have traded over $1,950,406 worth of Syndax Pharmaceuticals Inc stock and bought 210,921 units worth $2,347,816 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Luke Evnin a Briggs Morrison. On average, Syndax Pharmaceuticals Inc executives and independent directors trade stock every 50 days with the average trade being worth of $745,679. The most recent stock trade was executed by Keith A. Goldan on 14 June 2024, trading 1,250 units of SNDX stock currently worth $25,038.

What does Syndax Pharmaceuticals Inc do?

syndax pharmaceuticals is a biotechnology company located at 35 gatehouse dr., building d, floor 3, waltham, ma 02451.

Complete history of Mr. Meury stock trades at Syndax Pharmaceuticals Inc a Karuna Therapeutics Inc

Syndax Pharmaceuticals Inc executives and stock owners

Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Michael Metzger,
  President, Chief Operating Officer, Director
• Briggs Morrison,
  Chief Executive Officer, Director
• Dr. Briggs W. Morrison M.D.,
  CEO & Director
• Michael A. Metzger M.B.A.,
  Pres, COO & Director
• Michael Meyers,
  Senior Vice President, Chief Medical Officer
• Dennis Podlesak,
  Independent Chairman of the Board
• Pierre Legault,
  Independent Director
• Keith Katkin,
  Independent Director
• William Meury,
  Independent Director
• Fabrice Egros,
  Independent Director
• Jennifer Jarrett,
  Independent Director
• Peter Ordentlich,
  Chief Scientific Officer
• Luke Albrecht,
  Senior Vice President, General Counsel, Secretary
• Daphne Karydas,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Dr. Edward A. Sausville M.D., Ph.D.,
  Advisor
• Dr. Michael L. Meyers M.D., Ph.D.,
  Chief Medical Officer & Sr. VP
• Luke J. Albrecht,
  Sr. VP, Gen. Counsel & Sec.
• Alexander Nolte,
  Interim Principal Financial Officer, VP & Chief Accounting Officer
• Dr. Michael Downes Ph.D.,
  Co-Founder
• Dr. Ronald M. Evans Ph.D.,
  Co-Founder, Advisor and Chair of Scientific Advisory Board
• Dr. Richard A. Heyman Ph.D.,
  Co-Founder
• Dr. Peter Ordentlich B.Sc., Ph.D.,
  Co-Founder & Chief Scientific Officer
• Martin H. Jr. Huber,
  
• Neil Gallagher,
  President, Head of R&D
• Luke Evnin,
  Director
• Henry Chen,
  
• Partners L P/Ilbiotechnolog...,
  
• Steve M Sabus,
  Chief Commercial Officer
• Ivor Royston,
  Director
• Viii Associates, L.P.Blair ...,
  
• Vi Associates, L.P.Blair Ja...,
  
• Partners Vi, L.P.Blair Jame...,
  
• George W. Jr. Sledge,
  
• Bio Ventures Iv Qp Lp Scopa...,
  
• Partners Viii, L.P.Blair Ja...,
  
• Kim P. Kamdar,
  Director
• Richard P Shea,
  Chief Financial Officer
• Alexander Nolte,
  Chief Accounting Officer
• Catherine Madigan,
  Chief Medical Officer
• Keith A. Goldan,
  Chief Financial Officer